Cabometyx (cabozantinib)

pCPA File Number: 22062

Negotiation Status:

Concluded with an LOI

Indication(s):

Differentiated thyroid carcinoma (DTC), locally advanced or metastatic, in adult patients who are radioactive iodine-refractory (RAI-R) or ineligible, that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy

Sponsor/Manufacturer:

Ipsen Biopharmaceuticals Canada, Inc.

CDA-AMC Project Number:

PC0287-000

pCPA Engagement Letter Issued:

2023-04-25

Negotiation Process Concluded:

2023-09-14